Concepedia

Sharan K. Bagal

SK

Statistics

Publications

20

Citations

1K

H-Index

18

Active since

2009

Affiliations

Pfizer (United Kingdom)(Current)

AstraZeneca (United Kingdom)

Pfizer (United States)

AstraZeneca (United States)

AstraZeneca (Singapore)

Sharan K. Bagal is an author at Pfizer (United Kingdom) specializing in drug discovery, medicinal chemistry, and pharmacology.

ORCID

Publications per year

2009–2024

20

Publications

20

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Jessie Hao-Ru Hsu, Timothy Rasmusson, James Robinson et al. · Cell chemical biology · 2019 · 197 citations · Full text

, , +5

A novel selective and orally bioavailable <scp>N</scp> a <scp> <sub>v</sub> </scp> 1.8 channel blocker, <scp>PF</scp> ‐01247324, attenuates nociception and sensory neuron excitability

C. Elizabeth Payne, Adam R. Brown, Jonathon W Theile et al. · British Journal of Pharmacology · 2015 · 101 citations · Full text

, , +14

Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS<sup>G12C</sup>

Jason G. Kettle, Sharan K. Bagal, Sue Bickerton et al. · Journal of Medicinal Chemistry · 2020 · 85 citations · Full text

, , +17

The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain

S. Skerratt, Mark D. Andrews, Sharan K. Bagal et al. · Journal of Medicinal Chemistry · 2016 · 83 citations · Full text

, , +14

Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS<sup>G12C</sup>

Jason G. Kettle, Sharan K. Bagal, Sue Bickerton et al. · Journal of Medicinal Chemistry · 2022 · 63 citations · Full text

, , +17

1–5 of 20